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Hypoxia-mediated mitochondria apoptosis
inhibition induces temozolomide
treatment resistance through miR-26a/Bad/
Bax axis
Xin Ge1,2, Min-Hong Pan3, Lin Wang4, Wei Li5, Chengfei Jiang1, Jun He6, Khaled Abouzid7, Ling-Zhi Liu2,
Zhumei Shi8 and Bing-Hua Jiang1,2
ABSTRACT
Glioblastoma multiforme (GBM) is one of the most hypoxic tumors of the central nervous system. Although
temozolomide (TMZ) is an effective clinical agent in the GBM therapy, the hypoxic microenvironment remains a major
barrier in glioma chemotherapy resistance, and the underlying mechanisms are poorly understood. Here, we ﬁnd
hypoxia can induce the protective response to mitochondrion via HIF-1α-mediated miR-26a upregulation which is
associated with TMZ resistance in vitro and in vivo. Further, we demonstrated that HIF-1α/miR-26a axis strengthened
the acquisition of TMZ resistance through prevention of Bax and Bad in mitochondria dysfunction in GBM. In addition,
miR-26a expression levels negatively correlate with Bax, Bad levels, and GBM progression; but highly correlate with HIF-
1α levels in clinical cancer tissues. These ﬁndings provide a new link in the mechanistic understanding of TMZ
resistance under glioma hypoxia microenvironment, and consequently HIF-1α/miR-26a/Bax/Bad signaling pathway as
a promising adjuvant therapy for GBM with TMZ.
INTRODUCTION
Glioblastoma multiform (GBM), the most malignant
form of primary brain tumor in adults, is highly aggressive
and currently incurable. Although notable advancements
have been developed for GBM in the past 30 years, the
median survival of 12–15 months has not been appreci-
ably improved1. The chemo-resistance is still the worst
barrier in GBM treatment. Temozolomide (TMZ), the
current ﬁrst-line chemotherapeutic agent for GBM, is a
DNA alkylating antineoplastic drug that induces DNA
strand breaks during cell replication and promotes cell
apoptosis2,3. The crucial factors of TMZ resistance are
comprised of weak drug penetration due to hypoxia inside
the tumor and tumor cells’ strongly anti-apoptosis activ-
ity. Previous study indicated chemo-resistance can be
potentiated by hypoxia, a common feature in solid tumor.
The hypoxia-inducible factors (HIFs), the key transcrip-
tional regulator in response to hypoxia, facilitate tumor
progression and associate with poor survival4. The sup-
pression of HIF-1α has been investigated to sensitize
GBM cells to TMZ treatment5. However, the underlying
mechanism still remains elusive. Thus, the understanding
of the association between hypoxia and TMZ resistance is
essential to improve current anticancer strategies in GBM.
To survive in hypoxic conditions, cancer cells often
avoid apoptosis by altering their intrinsic gene expression
patterns. Recent studies shown that hypoxia-induced the
microRNAs (miRNAs) expression and these hypoxia-
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regulated miRNAs (HRMs) may be responsible for the
modulation of tumor-related genes in a low-oxygen
environment in GBM6,7. MiRNAs, the 18–22nt small
non-coding RNAs for regulating the development of
multiple tumors, are known as post-transcriptional
modulators by inhibiting translation of target mRNAs8–
11. The aberrant expression of hypoxia-regulated miRNAs
play key roles in GBM development, including cell pro-
liferation, apoptosis, and invasion12,13 as well as the sen-
sitize to TMZ in GBM therapy14–16. Notably, miR-26a
was identiﬁed to be strongly correlated with malignancy
in human GBM and received much attention in recent
years by targeting PTEN17. Our previous study also
demonstrated that miR-26a promoted tumor growth and
angiogenesis in glioma18. However, the mechanism of
miR-26a responses to hypoxia in GBM cells, and the
effects of miR-26a to TMZ treatment have never been
determined.
Apoptosis resistance is an important characteristic of
tumor cells. Mitochondria apoptosis is regulated by Bcl-2
family proteins which control the release of cyto-
chrome (Cyt) c from mitochondria. Bax and Bad are
known to mediate intrinsic mitochondrion-dependent
apoptosis19,20. They will permeabilize the outer mem-
brane and trigger the release of cytochrome c and sub-
sequently cascade activation of caspase family, which
leads to activation of key downstream proteins and con-
sequent genomic DNA damage19,21. Recent studies have
shown that treatment with TMZ may change the mito-
chondrial pathway of apoptosis by Bax and Bad22.
Nonetheless, the speciﬁc mechanism of Bax and Bad
regulation is still unexplored.
In the present work, we sought to investigate the
relationship between hypoxia and GBM chemotherapy
resistance, we plan to investigate whether miR-26a
upregulation in hypoxic microenvironment could
promote the TMZ resistance in GBM cells and whether
it may protect mitochondria dysfunction by inhibiting
pro-apoptosis factors such as Bax and Bad. Our ﬁnd-
ings would provide insights into GBM chemo-
resistance and clinical implication for cancer therapy
in the future.
RESULTS
Hypoxia induces resistance of glioma cells during
temozolomide treatment
The exposure of U87MG cells to hypoxia (1% O2)
resulted in a marked change of cell viability compared to
normoxia (20% O2) cultured cells. To evaluate the effects
of hypoxia on glioma chemo-resistance, we found sig-
niﬁcantly increased levels of HIF-1α from 6 to 48 h post
hypoxia treatment (Fig. S1a)23 and hypoxia decreased
glioma cells sensitivity to different doses of TMZ (Fig. 1a).
Subsequently, cell growth rate in the presence of TMZ
(250 μM) was assayed at different time points, and the
results indicated that hypoxia-induced glioma cell survival
upon TMZ treatment (Fig. 1b). The colony formation and
EdU proliferation assay also illustrated that U87MG cells
exposed to TMZ in hypoxic condition increased the
proliferating ability compared with that of normoxic
condition (Figs S1b-c). In order to test whether the
resistance to TMZ under hypoxia is caused by cell
apoptosis, FACS analysis showed that the apoptotic rates
of U87MG cells exposed to TMZ under the normoxic
condition were higher than that under the hypoxic con-
dition (Fig. 1c). To determine the mechanism of TMZ-
induced apoptosis under hypoxia, we found that the
exposure of U87MG cells to TMZ treatment increased
cellular cleaved caspase-3, cleaved PARP, and Bax
expression levels, but decreased Bcl-2 expression levels in
normoxic condition. However, hypoxia attenuated TMZ
treatment-induced cell apoptosis (Fig. 1d). Bcl-2 protein
family can protect cells from apoptosis via outer mito-
chondrial membrane permeabilization24. Thus, we
detected mitochondrial membrane potential (ΔΨm)
changes in TMZ-treated cells using ﬂuorescence micro-
scope and ﬂow cytometer after JC-1 staining, since JC-1
was able to selectively enter mitochondria and reversibly
shift the color between red and green as the membrane
potentials alter from high to low. The mitochondrial
membrane potentials are indicated by the red/green
ﬂuorescence intensity ratio. Compared with normoxic
condition, cells treated with TMZ under the hypoxia
condition showed a less impairment of ΔΨm with 50%
higher levels of red ﬂuorescence, which indicates the cell
survival (Fig. 1e, f). These results suggest that hypoxia
protects mitochondrial function and decrease the TMZ-
induced apoptosis.
TMZ is a kind of alkylating agent to cause DNA damage
and cell apoptosis. The phosphorylation of histone family
member X at serine 139 (γH2AX) is widely used as a
molecular marker for DNA double strands break (DSB)25.
Interestingly, our results showed that TMZ treatment
induced the expression levels of γH2AX, while hypoxia
reduced the augment of γH2AX in TMZ treatment
U87MG cells relative to the control cells (Fig. 1d). Fur-
thermore, Immunoﬂuorescence staining of γH2AX foci
showed that the number of γH2AX foci was increased in
the TMZ-treated U87MG cells and was attenuated under
hypoxic condition compared with normoxic condition,
suggesting that hypoxia helped inhibition of DNA damage
in U87MG cells (Fig. 1g). Thus, our data indicate that
hypoxic microenvironment protects the glioma cells from
apoptosis to TMZ treatment though protecting mito-
chondria function and decreasing apoptosis and DNA
damage.
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Mechanism of miR-26a induction by hypoxia
In order to test the differential expression of different
miRNAs in glioma chemo-resistance under hypoxic
conditions, quantitative real-time PCR (qRT-PCR) was
used to detect known key miRNAs in glioma. We found
miR-26a was one of the most signiﬁcantly changed miR-
NAs, which is closely associated with glioma clinical
stages, thus we selected miR-26a for further analysis
(Fig. S2a). We found that miR-26a was dramatically up-
regulated after 12 h or longer time under the hypoxia
condition, but was not changed signiﬁcantly up to 6 h
under the normoxia condition (Fig. 2a and S2b). Analysis
of genome data indicated that the mature form of miR-
26a is generated from 2 separate loci, miR-26a-1 and miR-
26a-2, co-expressed with their host genes CTDSPL and
CTDSP2, correspondingly. Thus, we detected the primary
forms and host genes of miR-26a under hypoxia and
found the expression levels of pri-miR-26a-1, pri-miR-
26a-2, CTDSPL, and CTDSP2 were increased as the same
trend with miR-26a (Fig. 2b and S2c). HIFs are known to
regulate a large expression proﬁle of genes under
hypoxia26. To investigate whether HIF-1 is involved, we
transfected the cells by overexpressing or depressing HIF-
1α expression under normoxia or hypoxia. Western
blotting showed plasmids transfection efﬁciency. Over-
expression of HIF-1α increased miR-26a expression, and
HIF-1α shRNA decreased miR-26a levels (Fig. 2c). The
expression of pri-miR-26a-1, pri-miR-26a-2, CTDSPL,
and CTDSP2 were up-regulated during overexpression of
HIF-1α, whereas HIF-1α shRNA had the opposite effect
(Fig. 2d, e and S2d, e). Furthermore, we found that there
are several HIF-1α response elements (HREs) in the
promoter region of miR-26a-1 and miR-26a-2 using
bioinformatics analysis. We selected regions containing
potential HRE sequences of miR-26a-1 and miR-26a-2
promoter and cloned into a luciferase reporter vector. The
luciferase activities of miR-26a promoter were increased
by HIF-1α overexpression under normoxia condition but
were decreased by shHIF-1α even under hypoxic
condition (Fig. 2f). ChIP assay was performed using
antibodies against IgG or HIF-1α followed by analysis of
qRT-PCR and showed that HIF-1α directly bound to the
promoter region of miR-26a and enhanced the expression
of miR-26a (Fig. 2g). To explore whether HIF-1α is
involved in mediating miR-26a expression in vivo, nude
mice were inoculated with U87MG cells, after two weeks,
treated with echinomycin (0.12 mg/kg) or bevacizumab
(10 mg/kg) every 2 days for 16 days. Then western blot-
ting and qRT-PCR were conducted, indicated that protein
levels of HIF-1α and mRNA expression of miR-26a in
tumors were repressed by echinomycin treatment and
increased by bevacizumab treatment (Fig. 2h, i). The
expression levels of HIF-1α and miR-26a in tumor tissues
were analyzed by immunohistochemistry and in situ
hybridization, respectively, which were consistent with
previous results (Fig. 2j). These results indicate that HIF-
1α also induces miR-26a expression in vivo. Taken toge-
ther, the results demonstrate that HIF-1α is a key
upstream inducer of miR-26a expression in glioma.
MiR-26a is important for TMZ treatment resistance
To analyze the role of miR-26a in glioma chemo-
resistance to TMZ treatment, U87MG cells were treated
at various TMZ concentrations. As Fig. 3a, compared with
control group, miR-26a overexpression signiﬁcantly sup-
pressed the chemo-sensitivity to TMZ. However, anti-
miR-26a inhibitor increased the chemo-sensitivity of the
cells to TMZ treatment. Similarly, inhibition of miR-26a
using anti-miR-26a inhibitor in U87MG cells signiﬁcantly
reduced growth rate and the ability to form a colony.
Overexpression of miR-26a promoted cell growth and
colony formation (Fig. 3b and S3a). In order to determine
whether miR-26a plays a key role in cell apoptosis in the
presence of TMZ treatment, overexpression of miR-26a
decreased the percentage of annexin V-positive cells,
whereas anti-miR-26a inhibitior treatment increased the
cell apoptosis rate with a concomitant TMZ treatment
(Fig. 3c). Furthermore, we examined the expression levels
(see ﬁgure on previous page)
Fig. 1 Hypoxic microenvironment improves tolerance of glioma cells to temozolomide though decreased DNA damage and protection
mitochondria function. a U87MG cells exposed to normoxic (20% O2) or hypoxic (1% O2) conditions were pretreated with TMZ of various
concentration for 72 h and subjected to CCK8 Assay. b U87MG cells exposed to normoxic or hypoxic condition were pretreated with TMZ (250 μM)
for indicated time points, then subjected to CCK8 Assay. c The apoptotic rates of U87MG cells exposed to normoxic or hypoxic condition upon
treatment with DMSO or TMZ (250 μM) for 72 h were measured by ﬂow cytometry. d Western blotting analysis showing levels of caspase-3, cleaved
caspase-3, PARP, cleaved PARP, Bax, Bcl-2, and γH2AX after indicated treatment. e, f The cells with treatment as indicated were stained with JC-1
probe and detected by ﬂuorescence microscope and ﬂow cytometer. Red ﬂuorescence represents the aggregate form of JC-1, indicating high
mitochondrial membrane potential (ΔΨm). Green ﬂuorescence represents the monomeric form of JC-1, indicating impaired mitochondrial
membrane potential (ΔΨm). g Immunoﬂuorescence staining of γH2AX in U87MG cells exposed to normoxia or hypoxia and TMZ (250 µM) or not for
72 h (magniﬁcation, ×400). Scale bar= 100 μm γH2AX: Green; DAPI: Blue. Data were presented by means ± SEM. in triple experiments. Asterisk
indicated signiﬁcant difference at P < 0.05 between normoxia group and hypoxia group. Double asterisk indicated signiﬁcant difference at P < 0.01
between control group and TMZ treatment group in normoxia. Double hash indicated signiﬁcant difference at P < 0.01 between normoxia group
and hypoxia group treated with TMZ
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of various apoptotic components and found that miR-26a
overexpression led to the inhibition of cleaved caspase-3
and cleaved PARP, and anti-miR-26a inhibitor increased
expression levels of those apoptotic associating proteins
(Fig. 3d). Meanwhile, to evaluate whether miR-26a has an
effect on the DNA damage and cell death after TMZ
treatment, our results showed that miR-26a may not
affect the expression of γH2AX in response to TMZ
treatment (Fig. S3b, c). Intriguingly, we found that miR-
26a inhibition induced transposition of cytochrome C in
mitochondria to cytoplasm for inducing cell apoptosis
(Fig. 3e). Then, the image using JC-1 probe by ﬂuorescent
microscope showed that TMZ induced mitochondrial
depolarization and cells changed from red to green in
both control groups as we showed in Fig. 1e before. MiR-
26a mimics increased the red/green ﬂuorescence intensity
ratio and anti-miR-26a inhibitor decreased that ratio,
suggesting that miR-26a protects mitochondrial function
(Fig. 3f). To further explore the effect of miR-26a on TMZ
resistance in vivo, tumor growth assay was performed and
monitored using pseudocolor bioluminescence images of
intracranial mice after TMZ treatment for 14 days. The
results showed that miR-26a overexpression made
U87MG cells to increase chemo-resistance and activity of
bioluminescence, while anti-miR-26a inhibitor enhanced
chemo-sensitivity and decreased activity of biolumines-
cence (Fig. 3g). T2-weighted MRI and hematoxylin and
eosin staining conﬁrmed this ﬁnding that tumors with
miR-26a-overexpression were bigger than those with
miR-NC, while anti-miR-26a inhibitor drastic attenuated
tumor growth (Fig. 3h). We found that miR-26a-
overexpressing tumors showed a lower apoptotic index
as demonstrated by active caspase-3 staining compared
with control tumors (Fig. 3i). Kaplan–Meier curves ana-
lysis showed that mice bearing miR-26a overexpression
tumors had a shorter survival than those bearing anti-
miR-26a inhibitor group (Fig. 3j). Thus, our results
demonstrate that miR-26a promotes TMZ resistance of
glioma cells by inhibiting apoptosis and protecting mito-
chondrial membrane integrity.
Bax and Bad are direct targets of miR-26a
To identify the mechanism of miR-26a in conferring
TMZ resistance, we predicted its potential downstream
targets using algorithmic programs (TargetScan and
MiRanda). Bcl-2 family genes, Bax and Bad are two can-
didate targets of miR-26a based on the pairing of the seed
sequence of miR-26a (Fig. 4a). To determine whether
miR-26a regulates Bax and Bad expression through
binding to their 3′-UTR, we made the wild (WT) or
mutant (Mut) luciferase reporter plasmids containing the
potential binding site of Bax and Bad 3’-UTR and per-
formed luciferase assay. As shown in Fig. 4b, miR-26a
decreased the luciferase activities of WT plasmids, but not
the Mut plasmids. Further study showed that the luci-
ferase activities of WT plasmids were reduced under
hypoxic condition compared with normoxic condition in
U87MG (Fig. 4c). To conﬁrm Bax and Bad are direct
targets of miR-26a, we identiﬁed if mRNAs of Bax and
Bad selectively enriched in the Ago2/RISC complex after
miR-26a overexpression using RNA-ChIP analysis
(Fig. 4d). As an internal positive control, miR-26a incor-
poration into RISC was signiﬁcantly increased after
transfection of miR-26a (Fig. 4e). As expected, Bax and
Bad signiﬁcantly elevated enrichment in miR-26a-
overexpressing cells compared with the miR-NC group
(Fig. 4f). The mRNA and protein levels of Bax and Bad
were inhibited by miR-26a mimics under the normoxia
condition, and increased by anti-miR-26a inhibitor under
the hypoxia condition (Fig. 4g, h). Furthermore, consistent
with the time-dependent increase of miR-26a upon
hypoxia, hypoxia also decreased the expression levels of
Bax and Bad in a time-dependent manner (Fig. S4a-b).
The results demonstrate that Bax and Bad are direct
targets of miR-26a.
(see ﬁgure on previous page)
Fig. 2 MiR-26a expression is upregulated under hypoxia through HIF-1α in glioma cells. a Quantitative real-time PCR (qRT-PCR) was performed
to measure time-dependent expressions of miR-26a after exposure to hypoxia for 0, 12, 24, or 48 h. b Measurement of pri-miR-26a-1 and pri-miR-26a-
2 among U87MG cells were showed in cells exposed to hypoxia compared with normoxia. c Upper: qRT-PCR was used to detect the expression of
miR-26a after transfection. Lower: The HIF-1α protein levels were examined by western blotting to conﬁrm the plasmids transfection efﬁciency. d, e
Expression levels of pri-miR-26a-1 and pri-miR-26a-2 were measured in cells overexpression or interference of HIF-1α. f U87MG cells were respectively
transfected with miR-26-1/2 promoter reporter plasmids and pCEP4-HIF-1α or shHIF-1α (psilencer), and relative luciferase activities were determined.
g Cells were exposed to normoxia or hypoxia for 24 h. ChIP assay was performed using antibodies against IgG or HIF-1α followed by analysis of qRT-
PCR. h Nude mice were inoculated with U87MG cells. And at day 14th after implantation, nude mice were treated with echinomycin (0.12 mg/kg) or
bevacizumab (10mg/kg) every 2 days for 16 days. HIF-1α expression was tested by western blotting to conﬁrm the establishment of the animal
models. i Expression levels of miR-26a in tumor masses were measured by qRT-PCR. j HIF-1α and miR-26a levels and locations in tumor tissues were
measured by in situ hybridization and immunohistochemistry, respectively. Scale bar= 100 μm. Data were presented by means ± SEM. in triple
experiments. Asterisk or hash indicated signiﬁcant difference at P < 0.05 compared with DMSO group. Double asterisk indicated signiﬁcant difference
at P < 0.01 compared with control group
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Bax and Bad are key targets of miR-26a in TMZ resistance
To determine the role of Bax and Bad in hypoxia-
induced TMZ resistance, Bax and Bad expression vector
and their small interference RNAs were ﬁrstly transfected
into U87MG cells, and western blotting results conﬁrmed
high transfection efﬁciency (Fig. S5a). Then CCK8 pro-
liferation assay showed that overexpression of Bax and
Bad in U87MG cells decreased miR-26a-induced resis-
tance to TMZ under normoxia, whereas knockdown of
Bax and Bad in U87MG cells increased anti-miR-26a-
suppressed sensitivity to TMZ under hypoxia (Fig. 5a).
Furthermore, cell growth rate, DNA synthesis rate (EdU
assay) and colony formation ability in the presence of
TMZ (250 μM) under normoxic or hypoxic conditions
were assayed. We found that forced expression of Bax or
Bad partially abolished miR-26a-induced cell resistance to
TMZ treatment, the higher ability of colony formation
and DNA synthesis rate under normal condition. Under
hypoxia, siBax or siBad restored anti-miR-26a-suppressed
chemo-resistance to TMZ, colony formation ability and
DNA synthesis rate in U87MG cells (Fig. 5b and S5b, d).
To further assess whether miR-26a, Bax and Bad involved
in cell apoptosis in the presence of TMZ under normoxic
or hypoxic conditions, FACS analysis revealed that over-
expression of miR-26a inhibited TMZ-promoted apop-
tosis activity under normoxia condition, which was
partially reversed by Bax or Bad overexpression. Also,
anti-miR-26a inhibitor promoted TMZ-induced apoptosis
under hypoxia condition, which was suppressed by siBax
or siBad (Fig. 5c). Next, after TMZ treatment, Bax or Bad
overexpression in U87MG/miR-26a increased cyto-
chrome C levels in cytoplasm and reduced that in mito-
chondria under normoxia. In U87MG/anti-miR-26a cell
line, siBax or siBad partly reversed the effect induced by
miR-26a inhibition (Fig. 5d). Furthermore, mitochondrial
functions were detected by JC-1 assay and immunocy-
tochemistry. Forced expression of Bax and Bad increased
miR-26a overexpression-decreased mitochondrial mem-
brane potential disruption, whereas knockdown of Bax
and Bad restored anit-miR-26a inhibitor-induced mito-
chondrial membrane potential disruption upon TMZ
treatment under the normoxia or hypoxia condition,
respectively (Fig. 5e). Mitotracker was used for mito-
chondria tracking and cytochrome C was the target pro-
tein (Fig. S5c). Thus, we discovered that miR-26a/Bax/Bad
axis contributes to hypoxic-mediated TMZ resistance by
inﬂuencing cytochrome C location, mitochondria func-
tion, and apoptosis.
To further evaluate the role of miR-26a/Bax/Bad axis on
TMZ resistance in vivo, the cells combination of miR-26a
or Bax /Bad were implanted intracranially in each mouse
and treated by TMZ at day 14 after implantation and
representative pseudocolor bioluminescence images of
intracranial mice were conducted. The results showed that
Bax/Bad overexpressiondecreased activities of biolumines-
cence and inhibited tumor growth, further conﬁrmed that
Bax/Bad overexpression promotes TMZ sensitivity of
glioma cells in vivo (Fig. 5f). T2-weighted MRI and hema-
toxylin and eosin staining conﬁrmed that mice bearing Bax/
Bad overexpression produced smaller tumor than miR-26a
(Fig. 5g). We also found that Bax/Bad overexpression
tumors showed a higher apoptotic index as demonstrated
by active caspase-3 staining compared with miR-26a group
(Fig. 5h). Kaplan–Meier curves were drawn to measure
mouse survival with tumor burden induced by U87/miR-
26a with or without Bax/Bad overexpression, and U87MG/
miR-26a with Bax/Bad overexpression showed a higher
survival rate (Fig. 5i). Taken together, our study ﬁrst
demonstrates that miR-26a/Bax/Bad axis contributes to
hypoxic-mediated TMZ resistance in vitro and in vivo.
(see ﬁgure on previous page)
Fig. 3 MiR-26a protects glioma cells mitochondrial function and promotes TMZ resistance in vitro and in vivo. a) CCK8 assay was performed
in U87MG cells stably expressing miR-NC, miR-26a, or anti-miR-26a inhibitor, with TMZ treatments at different concentrations for 72 h. b The cell
proliferation in 250 µM TMZ treatments was tested every 24 h in cells respectively. c U87MG cells were transfected with miR-NC, miR-26a mimic or
anti-miR-26a inhibitor for 48 h, then subjected to TMZ treatments (250 µM, 72 h). Cell death ratio was detected by ANXA5 and PI staining. The
apoptotic and secondary necrotic cells was shown as the sum of ANXA5-positive and ANXA5 and PI double-positive cells. Results were quantiﬁed as
the percentage of apoptosis ANXA5-positive and ANXA5 and PI double-positive cells in total cells and presented in the right panel. d Caspase-3,
cleaved caspase-3, PARP, cleaved PARP protein levels were detected in the stably expressing miR-NC, miR-26a, or anti-miR-26a cell lines. e Western
blot analysis showed cytochrome C levels of cytoplasm and mitochondria in the stably expressed miR-NC, miR-26a, or miR-26a-sponge cell lines after
TMZ treatments (250 µM, 72 h). β-actin and VDAC levels were served as the internal control of cytoplasmic and mitochondrial proteins, respectively. f
U87MG cells transduced with miR-NC, miR-26a mimics or anti-miR-26a inhibitor after treatment with TMZ (250 µM) for 12 h was stained with JC-1
probe and imaged by ﬂuorescent microscope. Scale bar= 100 μm. g U87MG/miR-NC, U87MG/miR-26a, and U87MG/ anti-miR-26a cells (1 × 105 cells)
were dispersed in 5 μL of Matrigel and were implanted intracranially in each mouse. Representative pseudocolor bioluminescence images of
intracranial mice bearing miR-NC, miR-26a, or anti-miR-26a transduced U87MG cells after treatment with TMZ at indicated time points. TMZ
treatment (20 mg/kg) group: n= 12 for miR-NC, n= 10 for miR-26a, n= 10 for miR-26a-sponge. h Intracranial tumors in brain were shown by T2-
weighted MRI and H&E staining. Scale bar= 1 mm. i Immunohistochemical (IHC) staining of tumor sections for cleaved caspase-3 signals. Scale bar:
100 μm. j Kaplan–Meier curves were drawn to measure the survival abilities of U87MG stable cell lines. Data were presented by means ± SEM in triple
experiments. Asterisk or hash indicated signiﬁcant difference at p < 0.05 compared with miR-NC or anti-miR-NC
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MiR-26a overexpression strongly correlates with HIF-1α,
Bax, Bad levels, and poor prognosis in GBM receiving
temozolomide therapy
To explore functional relevance of miR-26a and its
targets in clinic samples, we examined the expression of
miR-26a, Bax, and Bad mRNA in 9 normal brain tissues
and 32 human glioma specimens. Our results demon-
strated that the mRNA expression levels of Bax and Bad
were downregulated in glioma specimens while miR-26a
was upregulated (Fig. 6a). Spearman’s correlation analysis
determined that Bax, Bad levels were inversely correlated
with miR-26a levels in human glioma specimens (Fig. 6b).
To evaluate the clinical relevance of miR-26a and prog-
nosis of GBM patients, 10 matched pairs of primary GBM
and recurrent TMZ-refractory GBM were analyzed by
qPCR. The results conﬁrmed that miR-26a levels were
signiﬁcantly upregulated in the recurrent tumor samples
by contrast to their respective primary tumor tissues
(Fig. 6c). Moreover, the immunohistochemistry (IHC) and
in situ hybridization (ISH) demonstrated that the recur-
rent tumors exhibited signiﬁcantly higher HIF-1α and
miR-26a staining intensity compared with primary tumors
on the same set of GBM tissue (Fig. 6d). TCGA database
analysis showed that high expression levels of miR-26a
were consistently correlated with the poor clinical out-
come of GBM patients (Fig. 6e). Finally, we summarized
an ideograph to illustrate the crucial role of the HIF-1α/
miR-26a/Bax/Bad pathway on TMZ resistance process
(Fig. 6f). These results support the notion that a hypoxia-
miR-26a signaling pathway has an important role under
hypoxia-induced GBM chemo-resistance.
DISCUSSION
Hypoxia is a common microenvironment among dif-
ferent kinds of cancer tissues including GBM. Hypoxia
exerted crucial effects on different cellular and physiologic
processes including cell proliferation, apoptosis, metabo-
lism, and angiogenesis27–29. Moreover, tumor hypoxia is
associated with resistance to chemotherapeutic agents as
well as radiotherapy, ultimately limiting patient prog-
nosis30. In this study, we ﬁrstly demonstrated that hypoxia
improved tolerance of GBM cells to TMZ and promoted
tumor cells survival though decreasing DNA damage and
protecting mitochondria function. Thus, it is becoming
more important to elucidate the mechanism of TMZ
resistance in hypoxic conditions for GBM. Emerging
studies have shown that several miRNAs were dysregu-
lation during hypoxic conditions in cancer cells, such as
miR-210, miR-630, and miR-42131–33. Previously, we
showed that miR-26a expression levels were higher in
glioma species and promoted tumor growth and angio-
genesis in glioma. Here, we found a novel role of miR-26a
to enhance TMZ resistance of glioma cells in vitro and
in vivo models. Intriguingly, we also found that miR-26a
was upregulated by HIF-1α as the pivotal molecular reg-
ulator of oxygen homeostasis under hypoxic conditions.
TMZ is the GBM ﬁrst-line therapy in clinic; however,
patients who initially respond to therapy often develop
chemo-resistance to TMZ rapidly. The hypoxic micro-
environment as one of the main factors induced resistance
to TMZ by activating targets in the mammalian target of
rapamycin (mTOR) pathway and BIRC3 expression, but
speciﬁc mechanism is still not clear34. Generally, TMZ
ﬁghts against cancer cells by DNA damage and follow-up
apoptosis through the intrinsic pathway, which is also
known as mitochondria-dependent apoptosis35,36. A ser-
ies of studies illustrates the mechanism of apoptosis event
by several protein families; speciﬁcally the upstream Bcl-2
family (e.g., Bcl-2, Bax, and Bad) and the downstream
caspase family (e.g., caspase-3)37. According to this study,
Bcl-2 prevents cytochrome c release and caspase activa-
tion, which in turn promotes cytochrome c release into
the cytosol from mitochondria and activated cascade
activation of caspase activities38. The studies have shown
that treatment with TMZ changes pro-apoptotic Bax and
anti-apoptotic Bcl-2 expression levels involved in the
mitochondrial pathway of apoptosis39. However, the
mechanism how Bcl-2 family expression is driven by in
(see ﬁgure on previous page)
Fig. 4 Bax and Bad are direct targets of miR-26a. a The complementary pairing of miR-26a with Bax and Bad wild-type (WT) and mutant (Mut) 3′-
UTR reporter constructs were shown. b The reporter plasmids carrying the WT or Mut Bax and Bad 3′-UTR regions were co-transfected with miR-NC,
miR-26a mimics and pRL-TK into 293T cells. After 24 h of the transfection, the relative luciferase/pRL-TK activities were analyzed. c WT or Mut 3′-UTR
constructs of Bax and Bad were transfected into U87MG cells, then exposed to normoxia or hypoxia for 24 h. The relative luciferase/pRL-TK activities
were determined. d Immunoblotting was used to detect the Ago2-RISC complex by the Ago2 antibody from U87MG cells with miR-NC or miR-26a
mimics. Negative control was IgG. GAPDH was used as an internal control. e qRT-PCR was conducted to measure miR-26a levels incorporated into
RISC in cells overexpressing miR-26a and miR-NC. U6 RNA levels were used as an internal control. f qRT-PCR analysis was performed to measure levels
of indicated Bax and Bad mRNA levels incorporated into RISC derived from miR-26a or miR-NC cells. GAPDH levels were used as an internal control.
g, h U87MG cells exposed to normoxia or hypoxia were transfected with miR-26a mimics (100 and 150 nM) or anti-miR-26a inhibitor (100 and 150
nM). Bax and Bad expression levels were determined by immunoblotting and qRT-PCR using β-actin as an internal control. Data are presented as
mean ± SEM from three independent experiments. Asterisk indicates signiﬁcant difference at p < 0.05 compared with control group and double
asterisk indicates signiﬁcant difference at p < 0.01 compared with control group
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hypoxia-induced TMZ resistance in glioma still remains
unclear. Our study identiﬁed that Bax and Bad were direct
and functional targets of miR-26a and emerged the clin-
ical relevance, evidenced by the inverse correlations
between miR-26a and Bax/Bad in clinical tissues.
Our further studies using animal and human tumor tis-
sues suggests that miR-26a/Bax/Bad axis is important
in acquired TMZ resistance in glioma hypoxia
microenvironment.
Numerous studies showed that miR-26a had different
roles depending on tumor and tissue types, for example,
suppressor gene in lung cancer, melanoma, and breast
cancer, while oncogene in glioma40. In this study, the
TCGA database also conﬁrmed that high expression of
miR-26a correlated with poor survival in patients with
GBM, consistent with other studies. In recent years, the
contribution of HIF-1 to drug resistance has been
observed in diver tumor40. There new ﬁndings predict
that miR-26a expression levels could be used to indicate
therapeutic response to TMZ in GBM. And one of
interesting studies found that miR-26a levels were up-
regulated in lymph node metastasis tumor tissues in
contrast to primary tumor tissues, enhanced metastasis
potential of lung cancer cells41. It is well known that lung
cancer has a higher incidence of metastasis to the brain,
and TMZ combined with other therapies may have a
better effect on patients with brain metastasis from lung
cancer. Although the mechanism for the difference
between the primary tumor and metastases of lung cancer
is not clear, miR-26a should be further investigated as a
potential prognostic biomarker and therapeutic target for
TMZ chemotherapy resistance.
In summary, our results demonstrate that miR-26a is an
important regulator of TMZ resistance induced by
hypoxia, which can effectively protect mitochondria
function and reduce apoptosis by targeting bax and bad.
Our study signiﬁcantly broadens the understanding of
miR-26a in chemotherapy resistance. It is interesting to
evaluate whether targeting miR-26a may have potential
value as an adjuvant therapy in the future.
MATERIALS AND METHODS
Cell lines and reagents
U87MG and HEK293T cells were obtained from
American Type Culture Collection and were cultured in
Dulbecco’s Modiﬁed Eagle Medium (Gibco, Grand Island,
NY, USA) with 10% FBS. Temozolomide (TMZ) was
purchased from Selleck Chemicals (Shanghai, China).
Echinomycin was purchased from Sigma (St. Louis, MO,
USA). Bevacizumab was purchased from Roche (Welwyn
Garden City, UK). See Supplementary Table 1 for detail
information of antibodies.
Lentiviral packaging and stable cell line establishment
Lentivirus expressing miR-26a, miR-NC (negative con-
trol) and anti-miR-26a inhibitor were purchased from
Genepharma (Shanghai, China). Stable cell lines U87/
miR-NC, U87/miR-26a, and U87/anti-miR-26a were
established by infecting U87 cells with lentivirus, then
selected using puromycin (Sigma, MI, USA).
Cell proliferation and colony formation assay
To conﬁrm miR-26a effect on TMZ treatment, we
planted 3000 cells per well in 96-well plates. The
absorption value was measured by CCK8 kit (Dojindo
Laboratories, Kumamoto, Japan) at different time points
indicated. Data were obtained from three separate
experiments with six replications each time.
For colony formation assays, cells were placed in 24-
well plates with 200 cells per well. The medium was
changed every 4 days. Cells were ﬁxed with methanol 14
or 28 days later, stained with 0.05% crystal violet, photo-
graphed, and counted. We did triplicate for each group.
And experiments were independently repeated three
times.
(see ﬁgure on previous page)
Fig. 5 MiR-26a/Bax/Bad axis contributes to hypoxia-mediated TMZ resistance in vitro and in vivo. a Cell viability was analyzed by CCK8 assay
48 h after TMZ treatments as indicated. b Cell viability was tested every 24 h for different times with treatment of 250 µM TMZ. c, e Cell apoptosis and
mitochondrial membrane potential function were evaluated by ﬂow cytometry and JC-1 probe kit in U87MG cells with co-transfection miR-NC or
miR-26a mimics, with or without overexpression of Bax and Bad under normal condition. Meanwhile, U87MG cells with co-transfection anti-miR-NC
or anti-miR-26a mimics with or without siBax and siBad under hypoxic condition. U87MG cells exposed to normoxic or hypoxic condition were
pretreated with indicated TMZ treatments (250 μM), then subjected to apoptosis assay. Scale bar= 100 μm. d Western blot analysis showed
expression levels of cytochrome C in mitochondria and cytoplasm using stably expressing miR-NC, miR-26a, or anti-miR-26ainhibitor with indicated
treatment. f Representative pseudocolor bioluminescence images of intracranial mice bearing miR-26a with or without the overexpression of Bax and
Bad upon TMZ treatments. Cells were implanted intracranially in each mouse. 10 mouse each group. g T2-weighted MRI and H&E staining of brain
sections showed intracranial tumors. Scale bar= 1 mm. h IHC staining of cleaved caspase-3. Scale bar= 100 mm. i Kaplan–Meier curves were drawn
to measure mouse survival with the tumor burden induced by U87MG cells stably expressed miR-26a, with or without the overexpression of Bax and
Bad. Data are presented as mean ± SEM from three independent experiments. Asterisk indicates signiﬁcant difference at p < 0.05 compared with
control group, hash indicates signiﬁcant difference at p < 0.05 compared with control group and ampersand indicates signiﬁcant difference at p <
0.05 compared with control group
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EdU proliferation assay
Cell-Light™ EdU Apollo®488 In Vitro Imaging Kit
(Ribobio, Guangzhou, China) was performed as manu-
fracture instruction to determine cells proliferation. Cell
nuclei were stained for 30min by Hoechst 33342 at 5 µg/
mL. After incorporation, a ﬂuorescent dye making pos-
sible ﬂuorescent visualization of proliferating cells was
used that reacted speciﬁcally with EdU. Microscopic
observation was performed under a ﬂuorescence micro-
scope (ZEISS, Germany).
Fig. 6 MiR-26a overexpression positively correlates with HIF-1α, Bax, and Bad levels, and poor prognosis in GBM receiving temozolomide
therapy. a The expression levels of miR-26a, Bax and Bad in normal brain and glioma tissues. b Spearman′s correlation analysis determined the
correlation between expression levels of Bax, Bad, and miR-26a in human GBM specimens. c qRT-PCR analysis of miR-26a expression levels in primary
and recurrent glioma tissues from 10 patients who are treated with TMZ therapy regularly. d Representative images of IHC staining of HIF-1α and ISH
staining of miR-26a expression in a pair of primary and recurrent GBM tumors (×200 and ×400 magniﬁcation). Scale bar: 100 μm. e Based on TCGA
public datasets, Kaplan–Meier curves showed the negative correlation between miR-26a and clinical outcome. f The diagram summarizes our
ﬁndings: hypoxia induces activation of miR-26a by HIF-1α. HIF-1α/ miR-26a axis rescues Bax/Bad-driven mitochondrial membrane dysfunction and
subsequently, suppresses cytochrome c release and activation of caspase-3, which helps the GBM cell survive under TMZ treatment. Asterisk indicates
signiﬁcant difference at p < 0.05 compared with primary glioma tissue or normal tissue and double asterisk indicates signiﬁcant difference at p < 0.01
compared with primary glioma tissue or normal tissue
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Dual-luciferase reporter assay
For dual-luciferase assay, Bad or Bax 3′-UTR region
containing putative miR-26a matching sites (wide type,
WT) and corresponding mutant sites (Mut) were cloned
into the SacI and HindIII restriction enzyme sites of
pMIR-REPORTER vector (Ambion, CA, USA), immedi-
ately downstream of luciferase stop codon. Then we
transfected the Wild-type constructs and mutant ones
into the cells and co-transfected luciferase reporter plas-
mids containing either wild-type (WT) or mutant-type
(Mut) of Bad or Bax -3′UTR regions, pGL4.74 luciferase
reporter vector (Ambion) and miR-26a mimics or miR-
NC mimics, anti-miR-26a inhibitor or anti-miR-NC
inhibitor (Thermoﬁsher, US) using jetPRIME into U87
cells. Fireﬂy and Renilla luciferase activities were con-
ﬁrmed using a dual-luciferase assay kit (Promega, WI,
USA) at 24 h after transfection. Primers used for reporter
constructions were shown in Supplemental Table S2.
RNA isolation and quantitative real-time PCR (qPCR)
Total RNAs of cells were extracted using TRIzol reagent
(Takara, Dalian, China) from cultured cell or fresh tissues
following the manufacturer’s instructions. qPCR was
conducted to test expression of miR-26a and mRNA. U6
and GAPDH was used as an endogenous control. qPCR
using SYBR Premix DimerEraser (Takara, Dalian, China)
was performed on the 7900HT system. Relative expres-
sion levels of the target gene were determined by the
comparative cycle threshold method (2−ΔΔCt). Primers
used for qPCR were shown in Supplemental Table S1.
Protein extraction and western blotting
RIPA buffer (150 mM NaCl, 50 mM Tris, pH 7.4, 1%
Triton X-100, 1 mM EDTA) was used to lyse cells on ice
for 30min. The lysates were centrifugated at 13,000 rpm
4 °C for 15 min, and the supernatants were collected and
protein concentrations were determined using BCA assay
(Beyotime Institute of Biotechnology, China). Samples
were separated by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to PVDF membranes in
transfer buffer. Membranes were blocked with 5% nonfat
milk in 1 × PBS containing 0.05% Tween-20 and incu-
bated overnight with primary antibodies at 4 °C. The
protein bands were detected with appropriate horseradish
peroxidase conjugated secondary antibodies and reacted
with the SuperSignal West Pico Chemiluminescent Sub-
strate Kits (Thermo Scientiﬁc, MA, USA). Antibodies
used for western blotting were shown in Supplemental
Table S2
Flow cytometry analysis
Cells were treated with TMZ as indicated. ANXA5 and
PI was stained by the Alexa Fluor 488Annexin V Dead
Cell Apoptosis Kit (BD Pharmingen) as protocol. The
cells were analyzed by ﬂow cytometry (BD Bioscience,
FACSCalibur, Singapore), using 488 nm excitation and
measuring the ﬂuorescence emission at 530 and 585 nm.
FlowJo software were used to analyze data. Three
experiments were performed in triplicate.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed using the Simple ChIP
PlusEnzymatic Chromatin IP Kit (Agarose Beads) (Cell
Signaling Technology, USA). Cells were cross-linked by
addition of 37% paraformaldehyde at 37℃ for 20 min and
quenched by glycine. Then cells were rinsed with PBS
buffer. The extracted chromatin was digested and frag-
mented into 150 to 900 bp, then DNA was enriched from
the cell lysates by speciﬁc antibodies immunoprecipitating
HIF-1α or IgG overnight at 4 °C, and collected by incu-
bation with Protein A/G Agarose/Salmon Sperm DNA
(50% Slurry) for 2 h. The puriﬁed DNA was used as a
template for qPCR. Fold enrichment was analyzed
according to Ct as 2-Δ(ΔCt), where ΔCt=CtIP-CtInput
and Δ(ΔCt)=ΔCtantibody-ΔCtIgG. Sequences of Pri-
mers used in this study are listed in Supplementary
Table S2.
Isolation of RISC-associated RNA
U87MG cells transfected with miR-NC or miR-26a were
ﬁxed with 1% formaldehyde, followed by chromatin
fragmentation. Cells were lysed in NETN buffer and
incubated with Dyna beads Protein A (Invitrogen) toge-
ther with anti-pan Ago antibody (Millipore) or IgG con-
trol for immunoprecipitation. After proteinase K
digestion and extraction, the immunoprecipitated RNA
was acquired. Ethanol with glycogen was used to pre-
cipitate RNA.
Measurement of mitochondrial membrane potential
(ΔΨm) by ﬂuorescence microscopy
The mitochondrial membrane potential was analyzed by
ﬂuorescence microscopy using the 5,50,6,60-tetrachloro-
1,10,3,30-tetraethylbenzimidazol carbocyanineiodide
probe. After treatment as indicated, we mixed JC-1
staining solution (Beyotime, China) and culture medium
at the ratio of 5 μL per millilite and incubated the samples
in cell culturing incubator for 20min avoided from light.
After twice washing, cells were checked using a ﬂuores-
cence microscope (Zeiss, Germany).
Immunoﬂuorescence assay
Cells were treated using the procedure as indicated.
Then cells were incubated with 50 nM MitoTracker
Green to visualize mitochondria. Cells were ﬁxed 30 min
later with 37% paraformaldehyde and permeabilized with
PBS containing 0.5% Triton X-100 at room temperature.
And 1% bovine serum albumin (BSA) in PBST was used
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to block the samples. Bax and Bad antibodies was used for
immunostain overnight at 4 °C. The ﬂuorescence iso-
thiocyanate (FITC)-labeled goat anti-rabbit secondary
antibody (Santa Cruz) and tetramethylrhodamine iso-
thiocyanate (TRITC)-labeled goat antimouse secondary
antibody (Santa Cruz) were incubated with the samples.
Cells were incubated with 10 μM Hoechst 33342 for 10
min to visualize nuclei. Microscopic observation was
performed under a ﬂuorescence microscope (ZEISS,
Germany).
In situ hybridization
Parafﬁn-embedded tissues were sectioned at 5 μm and
then deparafﬁnized in xylenes. After above processes,
tissue slides were rehydrated through an graded ethanol
dilution series (from 100 to 70%). Slides were submerged
in diethylpyrocarbonate-treated water and subjected to
Hydrogen Peroxide treatment and Pepsin digestion,
reﬁxed in 4% paraformaldehyde, then slides were rinsed
with PBS between treatments. Slides were prehybridized
in hybridization solution at 38–42 °C for 60min. Then, 10
pmol probes (Boster, Wuhan, China) complementary to
miR-26a was added and hybridized for 20 h at a tem-
perature of 38–42 °C following washes in SSC at the same
temperature. After incubating with anti-DIG-HRP Fab
fragments conjugated to horseradish peroxidase, the
hybridized probes were measured by 3′-3-diaminobenzi-
dine solution, and nuclei were counterstained with
Haematoxylin.
Immunohistochemistry assay
Fresh tumor tissues were ﬁxed with Bouin solution for
24–48 h and processed by the parafﬁn-embedded method.
Deparafﬁnage and dehydration were as same as the pro-
cesses of in situ hybridization. Following, tissue slides
were heat immobilized or pepsin immobilized and incu-
bated with antibody against HIF-1α or Caspase-3 over-
night at 4℃. After incubated with secondary antibody, the
slides were reacted with DAB Histochemistry Kit (Invi-
trogen, USA).
In vivo study
Female BALB/c nude mice, 4 to 5 weeks old, were
purchased from Vital River Animal Center (Beijing,
China) and maintained in special pathogen-free (SPF)
condition for one week. Animal experimental procedures
were in consistent with the Care and Use of Laboratory
Animals Guide and approved by the Animal Experimental
Ethics Committee of Nanjing Medical University. Cells
(4 × 106) mixing with 150 μL of FBS-free DMEM medium
were subcutaneously injected into both sides of the pos-
terior ﬂanks of 5 nude mice per group. After implantation
for 24 days, mice were killed to dissect the tumor tissues.
Total proteins and RNAs were extracted for further
detection. Tumors were formalin-ﬁxed, parafﬁn-embed-
ded, and tumor sections at 5 μm were analyzed by
immunohistochemical staining for HIF-1α levels and by
hybridization in situ for miR-26a levels.
U87-Luc cells (1 × 105) with indicated virus infection or
treatment were resuspended in Matrigel in a total volume
of 5 μL and injected intracranially into the striatum of
adult nude mice (6-week-old) by a stereotactic device
(coordinates: 2 mm anterior, 2 mm lateral, 3 mm depth
from the dura). At one week after injection, the tumor-
bearing mice were intraperitoneally injected with 20mg/
kg TMZ in saline (ﬁnal DMSO concentration 25%). To
visualize the injected cells, mice were performed intra-
peritoneal injection with D-luciferin (150 mg/kg) and
formated of image under anesthesia with the IVIS Illu-
mina System (Caliper Life Sciences). Picture acquisition
was conducted once a week to supervise tumor growth.
After 6 or 8 weeks, brains were perfused with 4% paraf-
ormaldehyde by cardiac perfusion and further ﬁxed with
Bouin solution at 4 °C overnight. Then brains were
resected and performed H&E stainings.
Statistical analysis
Data shown in our study were represented as means ±
SD from at least three times independent experiments.
Student’s unpaired t-test was conducted for comparison
between two groups. Signiﬁcantly difference were con-
sidered when p < 0.05.
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